A time since onset of injection model for hepatitis C spread amongst injecting drug users

Journal of Mathematical Biology

Volumn 66, Issue 4-5, 2013, Pages 935-978

  Corson, S ^a   Greenhalgh, D ^a   Hutchinson, S J ^a,b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

Basic reproductive number; HCV; Hepatitis C; Injecting drug users; Mathematical model; Time since onset of injection

Indexed keywords

HEPATITIS C VIRUS;

EID: 84874217177     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-012-0577-y     Document Type: Article

References (48)

1. Advisory Council on the Misuse of Drugs (2009) The primary prevention of Hepatitis C among injecting drug users. http://drugs. homeoffice. gov. uk/publication-search/acmd/acmdhepcreport22835. pdf (accessed 2010).
2. Aitken CK, Lewis J, Tracy SL, Spelman T, Bharadwaj M, Bowden DS, Drummer H, Hellard ME (2008) High incidence of Hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48: 1749-1752.
3. Cassin S, Geoghegan T, Cox G (1998) Young injectors: a comparative analysis of risk behaviour. Ir J Med Sci 167: 234-237.
4. Corson S, Greenhalgh D, Hutchinson S (2011) Mathematically modelling the spread of hepatitis C in injecting drug users. Math Med Biol. doi: 10. 1093/imammb/dqr011.
5. Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S (2011) Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy 22: 102-108.
6. Diekmann O, Heesterbeek JAP (2000) Mathematical epidemology of infectious diseases: model building, analysis and interpretation. Wiley series in mathematical and computational biology. Wiley, Sussex.
7. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258: 135-140.
8. Frischer M, Leyland A, Cormack R, Goldberg DJ, Bloor M, Green ST, Taylor A, Covell R, McKeganey N, Platt S (1993) Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. Am J Epidemiol 138: 170-181.
9. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D (1998) Prevalence and incidence of Hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr 18: S11-S19.
10. Gatica JA, Smith HL (1977) Fixed point techniques in a cone with applications. J Math Anal Appl 61: 58-71.
11. Greenhalgh D (1993) Existence, threshold and stability results for an age-structured epidemic model with vaccination and non separable transmission coefficient. Int J Syst Sci 24: 641-668.
12. Greenhalgh D (1997) Bounds on endemic disease levels, risks and basic reproductive numbers in heterogeneous models for HIV/AIDS amongst injecting drug users. J Biol Syst 5: 151-180.
13. Gruer L, Cameron J, Elliot L (1993) Building a city wide service for exchanging needles and syringes. Br Med J 306: 1394-1397.
14. Hagan H, des Jarlais D (2000) HIV and HCV infection among injecting drug users. Mt Sinai J Med 67: 423-428.
15. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR (2002) Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186: 1558-1564.
16. Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON (2001) Prevalence of Hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 91: 38-42.
17. HPS (1990-1993) Health protection Scotland survey of Glasgow IDUs during 1990-1993. Health Protection Scotland, Glasgow.
18. HPS (2008-2009) Health Protection Scotland survey of Glasgow IDUs in 2008-2009. Health Protection Scotland, Glasgow.
19. Hutchinson S, Bird S, Taylor A, Goldberg D (2006) Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int J Drug Policy 17: 211-221.
20. Hutchinson S, Taylor A, Goldberg D, Gruer L (2000) Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990 to 1994: Implications for control and prevention of blood-borne viruses. Addiction 95: 931-940.
21. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, Parry J, Cameron S, Rhodes T, Ahmed S, Bird S, Fox R, Renton A, Stimson G, Goldberg D (2005) Prevalence of, and risk factors for, Hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12: 655-662.
22. Kapadia F, Vlahov D, des Jarlais DC, Strathdee SA, Ouellet L, Morse EVE, Williams I, Garfein RS, Second Collaborative Injection Drug User Study (CIDUS-II) Group (2002) Does bleach disinfection of syringes protect against Hepatitis C infection among young adult injection drug users? Epidemiology 13: 738-741.
23. Kaplan EH, O'Keefe E (1993) Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 23: 7-26.
24. Kretzschmar M, Wiessing L (2004) Modelling the transmission of Hepatitis C in injecting drug users. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L (eds) Hepatitis C and injecting drug use: impact, costs and policy options. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, pp 143-159.
25. Kreyszig E (1989) Introductory functional analysis with applications. Wiley, USA.
26. Lajmanovich A, Yorke JA (1976) A deterministic model for Gonorrhea in a non-homogeneous population. Math Biosci 28: 221-236.
27. Macey R, Oster G, Zahnley T (2000) Berkeley Madonna, UC Berkeley, USA. http://www. berkeleymadonna. com (accessed 2008).
28. Mathei C, van Dooreen S, Lemey P, van Damme P, Buntinx F, Vandamme A-M (2008) The epidemic history of hepatitis C among injecting drug users in Flanders. Belgium J Viral Hepat 15: 399-408.
29. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Valhov D, Thomas DL (2011) Changes in blood-borne infection risk among injection drug users. J Infect Dis 203: 587-594.
30. Mehta SH, Cox A, Hoovere DR, Wang X, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas D (2002) Protection against persistence of Hepatitis C. Lancet 359: 1478-1483.
31. Meyer CD (2000) Matrix analysis and applied linear algebra. SIAM, Philadelphia.
32. Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41.
33. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I (2007) High incidence of hepatitis C virus infection within a cohort of injecting drug users. J Viral Hepat 14: 413-418.
34. National Treatment Agency (2009) Does syringe cleaning work? http://www. harmreductionworks. org. uk/2_films/does_cleaning_syringes_work. html (accessed 2010).
35. NESI (2010) The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. Technical report, University of the West of Scotland and Health Protection Scotland and West of Scotland Specialist Virology Centre, Paisley.
36. Oden JT, Demkowicz LF (1996) Applied functional analysis: a first course for students of mechanics and engineering science (civil engineering and engineering mechanics series). CRC Press, Florida.
37. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R (2010) Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 202: 984-990.
38. Roy E, Alary M, Morissette C, Leclerc P, Boudreau J-F, Parent R, Rochefort J, Caessens C, Group TSW (2007) High Hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Sex Trans Dis AIDS 18: 23-27.
39. Roy E, Boudreau J-F, Boivin JF (2009) Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 102: 158-161.
40. Scottish Executive (2008) Hepatitis C action plan for Scotland, Edinburgh. http://www. scotland. gov. uk/Resource/Doc/222750/0059978. pdf (accessed 2011).
41. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
42. Sutton AJ, Gray NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M (2006) Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 6: 1-10.
43. Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R (2001) High risk injecting behaviour among injectors from Glasgow: cross sectional community wide surveys 1990-1999. J Epidemiol Community Health 55: 766-767.
44. Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R (2000) Prevalence of Hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 40: 176-183.
45. van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor J (1994) Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 70: 321-324.
46. Vickerman P, Hickman M, Judd A (2007) Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 36: 396-405.
47. Vickerman P, Platt L, Hawkes S (2009) Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect 85: 23-30.
48. World Health Organisation (2000) Hepatitis C Fact Sheet 164. World Health Organisation, Geneva, Switzerland. http://www. who. int/mediacentre/factsheets/fs164/en/ (accessed 2009).